This is a summary of the European public assessment report (EPAR) for NovoRapid. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use NovoRapid. For practical information about using NovoRapid, patients should read the package leaflet or contact their doctor or pharmacist.
Therapeutic Indication
### Therapeutic indication NovoRapid is indicated for treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.
Therapeutic Area (MeSH)
N/AATC Code
A10AB05
ATC Item
insulin aspart
Pharmacotherapeutic Group
Drugs used in diabetes
Active Substance (Summary)
INN / Common Names
N/A| Substance | CAS | Monograph |
|---|---|---|
| insulin aspart | N/A | 门冬胰岛素 |
EMA Name
NovoRapid
Medicine Name
NovoRapid
Aliases
N/ANo risk management plan link.
